Key details Compounded semaglutide and tirzepatide in injection and microdose injection formats are available
It is the target for several FDA-approved antidiabetic medications called incretin mimetics: These incretin mimetics are glucagon-like peptide 1 (GLP-1) analogs that mimic the physiological action of GLP-1 and thereby potentiates the incretin effect in type 2 diabetic patients
Additionally, those with severe inflammatory bowel disease (Crohn's disease or ulcerative colitis) may experience worsening diarrhea, nausea, or abdominal cramping, since GLP-1 agonists already cause gastrointestinal side effects in 3050% of users
Diabetes Care, 48 (7), e93e93
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use GLP-1 medications
GlucoVantage dihydroberberine What Makes GlucoVantage Stand Out